Impact of Baseline Sum of Longest Diameter in Target Lesions by RECIST on Survival of Patients with Metastatic Colorectal Cancer
Authors:
Open Access
- 5 September 2008
- journal article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 38 (10) , 689-694
Abstract
Objective In patients with metastatic colorectal cancer (mCRC), several prognostic factors such as performance status (PS), number of metastatic sites, carcinoembryonic antigen (CEA), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) have been reported. The objective of this study was to clarify the prognostic impact of Baseline Sum of Longest Diameter (BSLD) of target lesions by Response Evaluation Criteria in Solid Tumor (RECIST) in patients with mCRC. Methods The subjects of this study were consecutive 103 patients with mCRC who had been received the first line systemic chemotherapy between September 2002 and March 2005. Results The chemotherapy regimens included leucovorin-modulated 5-fluorouracil (5-FU) (n = 27) and 5-FU plus irinotecan (n = 76). The median overall survival time was 547 days. The median BSLD was 14.3 cm (range, 1.1–54.7). In univariate analysis, identified prognostic variables on survival were PS (0, 1 versus 2), number of metastatic sites (1 versus >1), peritoneal dissemination (+ versus −), pleural effusion (PE) and/or ascites, white blood cell (≥ versus 3), ALP (≥ versus P = 0.0059), PS (HR 0.248, 95% CI 0.107–0.577, P = 0.0012), PE and/or ascites (HR 0.402, 95% CI 0.228–0.708, P = 0.0016) were independent prognostic factors. Conclusion BSLD of target lesions by RECIST representing tumor volume might be an independent prognostic factor of patients with mCRC after systemic chemotherapy.Keywords
This publication has 21 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986Journal of Clinical Oncology, 2005
- Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal CancerJournal of Clinical Oncology, 2005
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acidEuropean Journal of Cancer, 1992
- Determinants of survival in patients with unresectable colorectal liver metastasesJournal of Surgical Oncology, 1989
- Hepatic Resection of Coiorectal MetastasesAnnals of Surgery, 1985
- Prognostic factors in advanced colorectal carcinomaThe American Journal of Medicine, 1983